We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

Back to rankings

8 hedge funds and large institutions have $160K invested in Northwest Biotherapeutics, Inc. Common stock in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% less capital invested

Capital invested by funds: $196K → $160K (-$36.3K)

27% less funds holding

Funds holding: 11 → 8 (-3)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
8
Holders Change
-3
Holders Change %
-27.27%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MSAM
Moloney Securities Asset Management
Missouri
+$2.65K

Top Sellers

Rank Fund Capital Flow
1
SL
Sentinus LLC
Illinois
-$3.55K
Name Holding Trade Value Shares
Change 		Change in
Stake
MSAM
1
Moloney Securities Asset Management
Missouri
$114K +$2.65K +11,600 +2%
VWA
2
VSM Wealth Advisory
Maryland
$15K – – –
OCG
3
Opus Capital Group
Ohio
$14K – – –
EFG
4
Ethos Financial Group
Pennsylvania
$6.51K – – –
WJWM
5
Williams Jones Wealth Management
New York
$6.17K – – –
KA
6
KLCM Advisors
Wisconsin
$2.28K – – –
AMG
7
Advisors Management Group
Wisconsin
$2K – – –
SL
8
Sentinus LLC
Illinois
– -$3.55K -12,925 Closed

NWBO Hedge Fund Activity: Q1 2025 in Review

8 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q1 2025, worth a combined $160K — down 18% from $196K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of NWBO and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Moloney Securities Asset Management, adding an estimated $2.65K. The largest seller was Sentinus LLC, exiting entirely with an estimated $3.55K sold.

  • 8 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q1 2025, down from 11 in Q4 2024.
  • Funds reported $160K of Northwest Biotherapeutics, Inc. Common stock stock for Q1 2025, down 18% quarter-over-quarter.
  • 0 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q1 2025 and 2 closed out, a net change of -2 holders.
  • The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q1 2025 was Moloney Securities Asset Management, an estimated $2.65K added.
  • The largest Northwest Biotherapeutics, Inc. Common stock seller in Q1 2025 was Sentinus LLC, an estimated $3.55K sold.

Based on aggregated 13F filings for Q1 2025.